The purpose of this long-term study was to look at the clinical relevance of soluble lectin-like oxidised low-density lipoprotein receptor 1 (sLOX-1) in rheumatoid arthritis patients. At three different time periods, we collected demographic and clinical data from a large rheumatoid arthritis cohort. At each time point, blood samples were obtained; there were 282 cases in 2012, 431 instances in 2013, and 500 cases in 2014. The enzyme-linked immunosorbent assay was used to detect plasma sLOX-1. The researchers looked for correlations between sLOX-1 and clinical data. Multivariate linear regression was used to examine the predictive variables related with changes in sLOX-1 and rheumatoid factor (RF). Plasma sLOX-1 levels were shown to be strongly linked to RF titer and other clinical indicators. Changes in sLOX-1 were shown to be strongly associated with changes in RF titers as well as those at baseline in longitudinal studies. Changes in RF and baseline RF were found to be predicting variables for changes in sLOX-1 in multivariate linear regression analysis. In all years, increases in RF were strongly associated with changes in sLOX-1. A stepwise regression study revealed that changes in sLOX-1 were a predictor of changes in RF.
The change in sLOX-1 has predictive value for measuring the change in RF, demonstrating sLOX-1’s use in clinical practise.
